Genentech Ocrevus Benefits in Disability Progression, Cognitive Decline in MS

 

• 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study
• 70% of patients with SPMS and PPMS demonstrated stable or improved cognition after one year of Ocrevus treatment in CONSONANCE
• Separate analysis on treatment disparities showed fewer Black and Hispanic patients with MS initiate high-efficacy treatments within two years of diagnosis
• Data at AAN support the body of evidence for Ocrevus more than 450,000 patient years and more than 225,000 patients treated globally

https://www.biospace.com/article/releases/new-data-for-genentech-s-ocrevus-ocrelizumab-show-benefit-in-disability-progression-and-cognitive-decline-in-both-secondary-progressive-and-primary-progressive-multiple-sclerosis/